Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Elizabeth L. Hougen Sells 1,523 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Elizabeth L. Hougen sold 1,523 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $32.44, for a total transaction of $49,406.12. Following the completion of the transaction, the chief financial officer now owns 110,500 shares of the company’s stock, valued at approximately $3,584,620. The trade was a 1.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ionis Pharmaceuticals Stock Performance

Shares of Ionis Pharmaceuticals stock traded up $0.23 on Monday, hitting $32.13. The stock had a trading volume of 1,662,595 shares, compared to its average volume of 1,661,709. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of -13.17 and a beta of 0.35. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a twelve month low of $31.03 and a twelve month high of $52.34. The business’s 50 day moving average is $35.07 and its two-hundred day moving average is $40.00.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IONS. William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Wells Fargo & Company lowered their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Piper Sandler lowered their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.65.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after buying an additional 303 shares during the period. Capital Performance Advisors LLP bought a new stake in Ionis Pharmaceuticals during the 3rd quarter worth approximately $40,000. Prospera Private Wealth LLC acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at approximately $42,000. Itau Unibanco Holding S.A. raised its stake in shares of Ionis Pharmaceuticals by 40.9% during the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after acquiring an additional 314 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Ionis Pharmaceuticals during the third quarter worth $51,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.